bioAffinity Technologies, Inc.
2.4800-0.01 (-0.4%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · BIAF · USD
Key Stats
Market Cap
11.16MP/E (TTM)
-Basic EPS (TTM)
-17.10Dividend Yield
0%Recent Filings
8-K
8-K
Validates CyPath Lung protocols
bioAffinity Technologies announced on October 20, 2025, a presentation at CHEST 2025 validating sputum storage and shipping protocols for its CyPath Lung test, which detects early-stage lung cancer with 92% sensitivity and 87% specificity in high-risk patients. The research, presented by Dr. Rossella Titone on October 22, underscores reliable home sample collection yielding results in two days. This bolsters CyPath Lung's noninvasive edge. Yet risks could alter outcomes.
8-K
Regains Nasdaq compliance
bioAffinity Technologies regained Nasdaq compliance on October 14, 2025, meeting the $1.00 minimum bid price and $2.5 million stockholders' equity rules after a hearings panel review. This secures continued trading of its common stock and warrants on the Nasdaq Capital Market. Yet a one-year mandatory monitor looms. Noncompliance with equity standards during monitoring triggers delisting risks without extra time.
8-K
Record CyPath® Lung sales surge
bioAffinity Technologies announced record-high sales for its CyPath® Lung diagnostic test in Q3 2025, surging 95% from the prior quarter amid growing adoption by Veterans' hospitals and mid-Atlantic expansion. Year-to-date through nine months, sales climbed 97% over 2024, with new patient volume up 77% and improved compliance for at-home sample collection. This momentum highlights the test's clinical value in early detection and avoiding invasive procedures. Yet risks to sustained growth persist, as noted in SEC filings.
8-K
1-for-30 reverse split announced
bioAffinity Technologies executed a 1-for-30 reverse stock split, effective September 18, 2025, at 4:01 p.m. ET, with trading on a split-adjusted basis starting September 19 on Nasdaq under BIAF. This move, approved by shareholders on July 25, reduces outstanding shares to approximately 1,338,029, aiming to meet Nasdaq's minimum bid price rule while preserving ownership percentages—fractional shares get cash payouts. Yet, it risks curbing stock liquidity.
IPO
Employees
Sector
Industry
BDSX
Biodesix, Inc.
6.54-0.01
BIO
Bio-Rad Laboratories, Inc.
319.47-10.95
CHEK
Check-Cap Ltd.
1.45-0.04
GNTLF
GENETIC TECHNOLOGIES
1.00+0.00
IDXG
Interpace Biosciences, Inc.
1.10-0.04
ILMN
Illumina, Inc.
95.03-2.77
LH
Labcorp Holdings Inc.
248.14-11.55
PRPO
Precipio, Inc.
20.66-0.34
TECH
Bio-Techne Corp
62.02-1.92
VCYT
Veracyte, Inc.
35.41-0.19